Material
T helper cells expressing IL-17 (Th17 cells) are major effector T cells in the intestine, but the regulation of their tissue tropism within the gut is poorly understood. We investigated the roles of vitamin A and retinoic acid in generation of inflammatory Th17 cells with distinct tissue tropisms within the intestine. We found that Th17 cells with distinct tissue tropisms and pathogenic activities are generated depending on the available concentration of retinoic acid (RA). In contrast to the widespread perception that RA would suppress the generation of Th17 cells, we provide evidence that RA is actually required for generation of Th17 cells with specific tissue tropisms within the gut. Th17 cells induced at suboptimal serum concentrations of RA migrated and induced moderate inflammation mainly in the large intestine, whereas the Th17 cells induced with optimal levels of exogenous RA (∼10 nM) migrated to the small intestine and induced more severe inflammation. The Th17 cells, induced in the presence or absence of RA, differentially expressed the trafficking receptors CCR9 and a4b7. CCR9 is required for Th17 cell migration to the small intestine, whereas a4b7 is required for the migration of Th17 cells throughout the whole intestine. Our results identified RA as a major signal that regulates the generation of gut Th17 cells with distinct capacities in migration and inflammatory activities. The results indicate also that specific gut tropism of Th17 cells is determined by the combination of trafficking receptors regulated by the RA signal. The Journal of Immunology, 2010, 184: 000-000.
T helper cells expressing IL-17 (Th17 cells) are highly enriched in the intestinal lamina propria (1) . They are present in all segments of the intestine, including the large and small intestine (2) . Certain groups of intestinal commensal bacteria provide the major signal for such enrichment of Th17 cells (3, 4) . Although it is thought that Th17 cells are major effector T cells that provide immunity against potential pathogens (5, 6) , the exact roles of Th17 cells in the intestine are incompletely understood. Th17 cells can induce or regulate the inflammation in the gut. Th17 cell cytokines are increased in various types of inflammatory bowel diseases (7) (8) (9) , and these cytokines have been implicated in the pathogenesis of inflammatory bowel diseases (1, 2, 10, 11) . In contrast, another Th17 cell cytokine IL22 has a protective role in colitis (12) . It is not well understood how Th17 cells acquire specific tissue tropisms and segmentspecific inflammatory activity within the intestine.
The intestine absorbs and metabolizes vitamin A into retinoic acid (RA), and RA is an important regulatory signal in the intestinal environment (13) (14) (15) (16) (17) . In this regard, RA is particularly associated with imprinting the tissue tropism of T cells and B cells for their migration into the small intestine (18) (19) (20) . It has been reported that RA can suppress the differentiation of naive T cells into Th17 cells, at least in vitro (19, (21) (22) (23) (24) . Together with its function in inducing FoxP3
+ regulatory T cells, RA is considered a key regulatory signal in inducing immune tolerance in the intestine (25) .
We investigated the role of RA in generation of Th17 cells with distinct tissue tropisms within the intestine. RA at physiologically relevant concentrations induced gut homing Th17 cells which are highly inflammatory upon transfer into mice. These cells were particularly active in migrating and inducing inflammation in the small intestine, whereas Th17 cells, generated in the presence of no or suboptimal concentrations of RA, induced inflammation mainly in the large intestine. We also report that the two gut-trafficking receptors CCR9 and a4b7 play distinctive roles in migration and function of the retinoid-induced Th17 (RA Th17) cells in eliciting inflammation in the intestine. Therefore, our results establish that distinct Th17 cell subsets with specific tissue tropism are generated depending on the available concentrations of RA. Our findings are important in understanding the origin, trafficking, and function of Th17 cells in the intestine.
Materials and Methods

Cell isolation and culture
Naive CD4 + T cells were isolated from pooled mononuclear cells of peripheral lymph nodes, mesenteric lymph nodes (MLNs), and spleens as described before (2) . Naive CD4 + T cells were cultured in complete RPMI 1640 medium (10% FBS) supplemented with Con A (2.5 mg/ml), hTGF-b1 (5 ng/ ml; PeproTech, Rocky Hill, NJ), mIL-6 (20 ng/ml; PeproTech), mIL-21 (10 ng/ml; PeproTech), mIL-23 (10 ng/ml; R&D Systems, Minneapolis, MN), mIL-1b (10 ng/ml; PeproTech), mTNF-a (20 ng/ml; PeproTech), anti-mIL-4 (11B11, 10 mg/ml; BioLegend, San Diego, CA), anti-mIFN-g (XMG2.4, 10 mg/ml; BioLegend) and anti-mIL-2 (S4B6, 2.5 mg/ml; BD Biosciences, San Jose, CA) for 7 d to generate control Th17 cells that were induced without exogenous All-trans-RA (hereafter called "RA"). RA Th17 cells were prepared using the same condition with RA at physiologic concentrations (10-20 nM) . In some experiments, naive T cells were CFSE-labeled and cultured in the Th17 cell induction condition to determine the relationship between cell division and expression of the gut-trafficking receptors (Supplemental Fig. 1 ). The Th17 cells were also recultured for an additional 7 d to determine the stability of trafficking receptor expression (Supplemental Fig. 2 ).
Animals and generation of vitamin A-deficient or -sufficient mice
All the experiments with animals in this study were approved by the Purdue University Animal Care and Use Committee. CCR9-deficient mice were described previously (26) . Integrin (Itg) b7-deficient mice (C57BL/6-Itgb7 tm1Cgn /J) and Rag1-deficient (B6.129s7-Rag1 tm1Mom /J) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). AKR/J mice (The Jackson Laboratory) were kept on custom research diets based on AIN-93G containing 25,000 IU/kg or 0 IU/kg levels of retinyl acetate (Harlan Teklad TD-06528 and 07267) immediately following birth. The pups were weaned at 4 wk old and maintained on the same diets for an additional 9 wk. Vitamin A deficiency was verified by determining defective CCR9 expression by small intestinal T cells, as described previously (2). 
Flow cytometry to identify Th17 cells and to determine their expression of trafficking receptors
Intracellular cytokine staining for IL-17 (TC11-18H10.1; BioLegend) expression was performed as described previously after activation with phorbol 12-myristate 13-acetate (50 ng/ml) and ionomycin (1 mM) in the presence of monensin (10 mg/ml) (2). Before activation, the cells were stained for surface expression of CD4 (clone RM4-5; BioLegend), CD44 (clone IM7; BioLegend), CCR9 (clone 242504; R&D Systems), a4b7 (clone DATK32; BioLegend), and/or aEb7 (Clone 2E7; BioLegend). Stained cells were analyzed using a BD Canto II (BD Biosciences).
Homing experiment
Th17 cells generated in vitro (1 3 10 7 cells per mouse) were labeled with CFSE or tetramethylrhodamine isothiocyanate (TRITC) and coinjected into wild type C57BL/6 mice via a tail vein; ∼20 h later, the mice were sacrificed and single cell suspension was prepared from selected organs after collagenase digestion (2) The percent distribution of injected Th17 cells ( Fig. 1E ) was calculated based on the numbers of migrated cells into the indicated organs.
Chemotaxis
Chemotaxis was performed using Transwells (Corning Glass, Corning, NY) with 5-mm pores as described previously (27) . Optimal concentrations of CCL25 (2.5 mg/ml) and CCL19 (1 mg/ml), determined by a preliminary titration experiment, were used.
In vivo intestinal inflammation study to assess the effector function of Th17 cells
/J mice were injected i.p. with 1 3 10 6 control or RA-induced Th17 cells. Weight change was monitored, and the mice were sacrificed on day 30-32 postinjection when some mice became moribund. Intestinal inflammation in Rag1-deficient mice was scored as previously described with some modification (27) . We scored the degree of inflammation and the degree of mucosal hyperplasia and loss of villi on a scale of 0-4. The two scores were combined to obtain the final inflammation index. The histologic images were obtained with a bright-field Leica (Leica Microsystems, Deerfield, IL) microscope equipped with a color camera at 3200 magnification.
Confocal analysis to determine localization of injected Th17 cells
Indicated tissues (spleen, peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches [PPs]) were harvested from euthanized mice that were previously injected with cells stained with TRITIC and CFSE, and frozen in Tissue-Tek (Sakura, Torrance, CA). Six-micrometer frozen tissue sections were fixed in acetone and stained with anti-CD3-APC. A Zeiss LSM 710 confocal microscope system (Zeiss, Thornwood, NY) was used to image the cells within the tissues.
Statistical analyses
Student paired and unpaired two-tailed t tests were used to compare the significance of differences in means of two groups of related or unrelated data. p # 0.05 was considered significant.
Results
Naive T cells differentiate into CCR9
+ a4b7 + Th17 cells at physiologic concentrations of RA RA (i.e., All-trans-RA or At-RA) is the major biologically active metabolite of vitamin A. To determine the role of RA in induction of gut homing Th17 cells, we activated naive T cells in a Th17 cell-inducing condition in the presence of increasing concentrations of RA. The induction of Th17 cells was reduced but still occurred at significant levels in the presence of RA lower than 30 nM (Fig. 1A) . Severe reduction occurred only at high concentrations of RA ($100 nM). An interesting feature of these RA Th17 cells was the expression of CCR9 and a4b7 (Fig. 1B) ; however, they poorly expressed CD103 (or aEb7), another mucosal homing receptor (Supplemental Fig. 3) . Compared with CCR9, a4b7 was more readily expressed by the Th17 cells at low (∼1 nM) RA concentrations (Fig. 1B) . a4b7 was induced at a medium level, even in the absence of exogenous RA, perhaps in response to the basal level of RA present in the serum. The induction of CCR9 and a4b7 on Th17 cells by RA was prompt, occurring after one to two cell divisions following T cell activation (Supplemental Fig. 1 ). Only RA Th17 cells were able to migrate to the CCR9 ligand CCL25 (Fig. 1C) . Expression of a4b7 induced by RA was relatively more stable than that of CCR9 on Th17 cells upon subsequent T cell activation in the absence of RA (Supplemental Fig. 2 ). In contrast, CCR9, once induced on Th17 cells by RA, quickly disappeared upon restimulation of Th17 cells in the absence of exogenous RA.
The RA-induced Th17 cells preferentially migrate to the small intestine We performed a short-term (20 h) homing assay to determine whether RA Th17 cells, induced in the presence of exogenous RA, have the homing potential to the intestine. Upon i.v. injection, the Th17 cells preferentially migrated to the small intestine (Fig. 1D,  1E ). RA Th17 cells, when compared with control Th17 cells (induced in the absence of exogenous RA), were somewhat less efficient in migration to non-small intestine tissues (Fig. 1D) . Within the small intestine, the lamina propria is the preferential destination of RA Th17 cells (Fig. 1F) . In spleens, PPs, and lymph nodes, both the injected RA and control Th17 cells were found in the T cell area of the lymphoid tissues.
Th17 cells are decreased specifically in the small intestine of vitamin A-deficient mice
The results shown in Fig. 1 that RA induced gut homing Th17 cells is surprising, because it has been reported that RA suppresses the induction of Th17 cells from naive T cells in vitro. To determine whether vitamin A is required for the presence of Th17 cells in vivo, we induced vitamin A deficiency in mice and examined the frequency of Th17 cells in different organs, including the intestine. We found that the frequencies of Th17 cells were decreased in the small intestine and PPs of vitamin A-deficient mice ( Fig. 2A, 2B) . However, the numbers in spleen and MLNs were unchanged. The data suggest that vitamin A has a tissue-specific role in population of Th17 cells, and it supports the role of RA in generating small intestine homing Th17 cells.
Differential roles of a4b7 and CCR9 in migration of gut-homing Th17 cells
Next, we investigated the function of a4b7 and CCR9 in the migration of Th17 cells. First, we compared Th17 cells derived from wild type and integrin b7 (Itgb7)-deficient mice (Fig. 3A) . Itgb7 is a subunit for both aEb7 and a4b7. Because RA Th17 cells have low expression of ItgaE (Supplemental Fig. 3) , most of the Itgb7 subunit would be paired with the a4 subunit. We performed a 20 h short-term homing assay to compare wild type and Itgb7-deficient RA Th17 cells in migration to various organs. The migration of Itgb7-deficient Th17 cells to the intestine including MLN, PP, small intestine, colon, and cecum was defective (Fig.  3B) . Instead, the migration of these Th17 cells to other nongut tissue sites, such as peripheral lymph nodes (313% 6 52), spleen (235% 6 9.5), liver (166% 6 48), and marrow (206% 6 78), was generally enhanced. The Itgb7-deficient Th17 cells failed to enter MLNs, PPs, and the lamina propria of the intestine (Fig. 3C) .
When CCR9-deficient RA Th17 cells were compared with wild type Th17 cells (Fig. 4A ), they were defective in migration only to the small intestine lamina propria (Fig. 4B, 4C) . Although not statistically significant, the migration of CCR9-deficient RATh17 cells to other mucosal tissues, such as MLNs (163% 6 34), the colon (180% 6 56), PPs (155% 6 30), and the peritoneal cavity (148% 6 16), was increased (Fig. 4B) . Overall, compared with a4b7, CCR9 had a more specific role in the migration of Th17 cells to the small intestine lamina propria.
RA regulates the gut tissue tropism of Th17 cells in pathogenesis
We hypothesized that RA Th17 cells and control Th17 cells would induce inflammation in different locations of the intestine because these two T cell populations have different tissue tropisms. To test this hypothesis, the RA Th17 cells and control Th17 cells were separately injected i.p. into Rag1-deficient mice. We found that RA Th17 cells induced greater weight loss compared with control Th17 cells that were induced in the absence of RA (Fig. 5A ). Mice injected with control Th17 cells had more severe inflammation in the distal colon than in the small intestine. In contrast, mice injected with RA Th17 cells had the most severe inflammation in the small intestine (Fig. 5B, 5C ). The inflammation in the small intestine was accompanied by mucosa/crypt hyperplasia and loss of villi (Fig. 5B, 5C ). The inflammation consisted primarily of infiltration by lymphocytes and macrophages with fewer neutrophils and occasional eosinophils. In support of the tissue tropism of RA Th17 cells, many more Th17 cells were found in the Rag1-deficient mice injected with RA Th17 cells compared with control Th17 cells, even ∼30 d after the injection of the Th17 cells (Supplemental Fig. 4 ). In contrast, there was no statistically significant difference in numbers of Th1 and T regulatory cells in the small intestine. Overall, the RA Th17 cells and control Th17 cells induce inflammation largely in distinct segments of the intestine.
The higher inflammatory activity of RA Th17 cells could be due to their differences in expression of trafficking receptors and migration ability. Alternatively, this is due to other nonmigratory features of the cells. We compared the inflammatory activities of wild type and CCR9 or Itgb7-deficient RA Th17 cells (Fig. 6A) . We found that both CCR9 ( 2/2 ) RA Th17 cells and Itgb7 ( 2/2 ) RA Th17 cells had decreased inflammatory activities compared with wild type RA Th17 cells. Particularly, the Itgb7 deficiency completely blocked the inflammatory activity of RA Th17 cells in all segments of the intestine (Fig. 6B) . In contrast, CCR9 deficiency led to blockade of inflammation largely in the small intestine (Fig. 6C) . The decreased inflammation by CCR9 ( 2/2 ) RA Th17 cells and Itgb7 ( 2/2 ) RA Th17 cells was consistent with decreased numbers of Th17 and Th1 cells in the small intestine (Fig. 7) . Moreover, the number of Th1 cells was decreased in the large intestine of the mice injected with Itgb7 ( 2/2 ) RA Th17 cells. FoxP3 + T cells were increased in the spleen and large intestine of the mice injected with CCR9 ( 2/2 ) or Itgb7 ( 2/2 ) Th17 cells. These results
show that the two trafficking receptors that are induced by RA-CCR9 and a4b7-have essential functions in induction of the intestinal inflammation initiated by RA Th17 cells.
Discussion
We report the presence of Th17 cell subpopulations with distinct in vivo tissue tropism that is regulated by the RA signal. The tissue tropism of these Th17 cells is determined by differential expression of gut homing receptors. Strikingly, the Th17 cell subpopulations with different tissue tropism induced inflammation in different parts of the intestine. We believe that this is the first demonstration of the presence of Th17 cell subsets with inflammatory activities in distinct compartments of the intestine.
What concentration of RA is really available for T cells undergoing Ag activation in vivo? The RA concentration in normal human blood plasma is ∼4.9 ng/ml (28) . Comparably, ∼2 ng/ml of RA was detected in rat serum. It is estimated that 50-75% of the RA in serum or plasma is At-RA. Therefore, the concentration of At-RA in normal blood plasma is estimated to be ∼5 nM. The balance between RA-synthesizing retinaldehyde dehydrogenases and RA-inactivating cytochrome P450RAI (CYP26) determines the availability of RA in a given tissue microenvironment. The expression patterns of CYP26 and RA-synthesizing retinaldehyde dehydrogenase type 2 are largely complementary in developing embryos (29) (30) (31) , and it is expected that a similar pattern of complementary expression of the two enzymes would occur in adults. Based on the sensitivity of the expression of CCR9 and a4b7 in response to RA, it is estimated that the intestinal Agpriming environment would have at least 2-3 nM and potentially higher levels of active RA (,30 nM). The concentration of RA in peripheral lymph nodes, where CCR9 is not induced, is expected to be ,1 nM. We estimate that RA levels between 0.1 and 30 nM are within the physiologic range. RA concentrations higher than this range could be found in vivo but the need for that high RA signal is unclear.
A most characteristic feature of the Th17 cells induced at physiologic levels (10-20 nM) of RA is the expression of both CCR9 and a4b7. These two trafficking receptors are somewhat different from each other in requirement for RA for persistent expression. a4b7 initially induced by RA persists, even after subsequent Ag priming in the absence of exogenous RA. In contrast, expression of CCR9 on Th17 cells is transient requiring continued presence of RA. Moreover, CCR9 is not induced well in response to RA on the Th17 cells that were previously activated in the presence of suboptimal concentrations of RA. We found that a4b7 is a general homing receptor of Th17 cells for the intestine and associated lymphoid tissues, whereas CCR9 is a receptor more specific for the small intestine. This finding suggests that at least several populations of Th17 cells (CCR9 + a4b7 + , CCR9 be generated in different sites of the intestine, depending on the RA availability during repetitive priming processes. The potent activity of retinoid-induced Th17 cells in inducing small intestine inflammation is notable and is associated with the expression of a4b7 and CCR9. a4b7 is widely expressed by intestinal lymphocytes and serves as the major homing receptor (32, 33) . a4b7 is an adhesion molecule for MAdCAM-1 (32, 34) and can guide the Th17 cells to the entire gut system. It appears that even basal levels of a4b7, induced in the presence of low (serum) levels of RA, are required for migration of Th17 cells into the intestine and associated lymphoid tissues. Thus, higher expression of a4b7, induced at optimal levels of RA over the physiologic range, confers Th17 cells with the enhanced ability to stay within the intestine and to induce inflammation. CCR9 is expressed more specifically by the T cells in the small intestine and acts as a homing receptor that is specific for this tissue (35) (36) (37) (38) . CCR9 can guide the Th17 cells to the small intestine lamina propria compartment close to epithelial cells where CCL25 is expressed (35, 39, 40) , and therefore would cause the more focused migration and inflammation in the small intestine. Consistently in our study, Itgb7 deficiency had a broader effect on Th17 cell migration to the intestine, whereas CCR9 deficiency had a specific effect on their homing to the small intestine. In line with the differential roles of these trafficking receptors in determining the tissue tropism of Th17 cells, Itgb7 deficiency had greater impact than CCR9 deficiency on the inflammatory activity of the retinoid-induced Th17 cells. This finding is supported by the fact that, without proper expression of Itgb7 or a4b7, Th17 cells fail to migrate to any site of the entire intestinal system, including the small intestine, despite their normal expression of CCR9. This finding is in line with the established roles of these trafficking receptors for other T cells (32, 33, 35, 39, 40) , and it suggests that Th17 cells do not deviate from the general trafficking behavior of gut T cells. Some studies have reported that IL-22 has a protective role in intestinal inflammation (12, 41) , whereas others reported proinflammatory roles of IL-22 in intestinal inflammation (42, 43) . We would like to point out that there was no significant difference in expression of IL-22 by control and RA Th17 cells (Supplemental Fig. 5) .
Because of the previously reported in vitro phenomenon that induction of Th17 cells is suppressed by RA (19, 22, 23) , it has been assumed that vitamin A antagonized the population of Th17 cells in the intestine. Our finding with vitamin A-deficient mice indicates that the RA signal is actually important for the presence of Th17 cells in the small intestine. A similar decrease of small intestine Th17 cells in vitamin A deficiency was observed in a mouse model of chronic intestinal inflammation (44) , suggesting that it occurs broadly in both normal and inflammatory conditions. We do not rule out the possibility that induction of Th17 cells could be somewhat suppressed by the RA in the small intestine in vivo. However, the increase of gut homing receptor-expressing Th17 cells would compensate for this small decrease caused by the presence of RA. Thus, there would be an overall increase in the number of gut Th17 cells in the intestine in response to RA.
Our results provide useful targets of intervention in regulation of the inflammatory activities of Th17 cells in the intestine. It is possible to regulate the inflammatory activity of Th17 cells in the small versus other compartments of the intestine by selective blocking of CCR9 or Itgb7. This projection is well supported by therapies approved by the U.S. Food and Drug Administration and other proposed therapies targeting a4 or a4b7 integrin. For example, blocking of the Itga4 using mAbs to integrin a4 is a treatment for Crohn's disease approved by the U.S. Food and Drug Administration (45) . It was also shown to be effective in the amelioration of colitis in animal models (45) (46) (47) . Whereas this therapy targets all a4 integrins including a4b7 and a4b1, mAbs more specifically blocking Itgb7 or MAdCAM-1 were also effective in inhibiting colitis in animal models (48, 49) . We propose that these reagents can act on the a4 integrins of Th17 cells and can therefore block their migration and inflammatory activities in the intestine. If the inflammatory activity of Th17 cells is localized to the small intestine, blocking of CCR9 would be more specific in treating the localized inflammation without the potential side effects of broad immune-suppression in the body.
